📣 VC round data is live. Check it out!

Sight Sciences Valuation Multiples

Discover revenue and EBITDA valuation multiples for Sight Sciences and similar public comparables like Affluent Medical, Profound Medical, Orchestra BioMed, Stratec and more.

Sight Sciences Overview

About Sight Sciences

Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.


Founded

2010

HQ

United States

Employees

216

Financials (LTM)

Revenue: $81M
EBITDA: ($25M)

EV

$193M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Sight Sciences Financials

Sight Sciences reported last 12-month revenue of $81M and negative EBITDA of ($25M).

In the same LTM period, Sight Sciences generated $70M in gross profit, ($25M) in EBITDA losses, and had net loss of ($39M).

Revenue (LTM)


Sight Sciences P&L

In the most recent fiscal year, Sight Sciences reported revenue of $77M and EBITDA of ($26M).

Sight Sciences is unprofitable as of last fiscal year, with gross margin of 86%, EBITDA margin of (34%), and net margin of (50%).

See analyst estimates for Sight Sciences
LTMLast FY202320242025202620272028
Revenue$81M$77M$81M$80M$77M
Gross Profit$70M$67M$69M$68M$67M
Gross Margin86%86%85%85%86%
EBITDA($25M)($26M)($49M)($46M)($33M)
EBITDA Margin(30%)(34%)(61%)(57%)(42%)
EBIT Margin(48%)(48%)(71%)(63%)(48%)
Net Profit($39M)($38M)($56M)($52M)($38M)
Net Margin(48%)(50%)(69%)(64%)(50%)

Financial data powered by Morningstar, Inc.

Sight Sciences Stock Performance

Sight Sciences has current market cap of $236M, and enterprise value of $193M.

Market Cap Evolution


Sight Sciences' stock price is $4.34.

Sight Sciences share price decreased by 10.7% in the last 30 days, and increased by 5.8% in the last year.

Sight Sciences has an EPS (earnings per share) of $-0.71.

See more trading valuation data for Sight Sciences
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$193M$236M-4.3%-10.7%15.1%5.8%$-0.71

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Sight Sciences Valuation Multiples

Sight Sciences trades at 2.4x EV/Revenue multiple, and (7.8x) EV/EBITDA.

See NTM and 2027E valuation multiples for Sight Sciences

EV / Revenue (LTM)


Sight Sciences Financial Valuation Multiples

As of June 3, 2026, Sight Sciences has market cap of $236M and EV of $193M.

Sight Sciences has a P/E ratio of (6.1x).

LTMLast FY202320242025202620272028
EV/Revenue2.4x2.5x2.4x2.4x2.5x
EV/EBITDA(7.8x)(7.4x)(3.9x)(4.2x)(5.9x)
EV/EBIT(5.0x)(5.2x)(3.4x)(3.8x)(5.2x)
EV/Gross Profit2.8x2.9x2.8x2.8x2.9x
P/E(6.1x)(6.1x)(4.3x)(4.6x)(6.1x)
EV/FCF-(6.4x)(4.0x)(8.5x)(6.4x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Sight Sciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Sight Sciences Margins & Growth Rates

Sight Sciences grew revenue by 11% but EBITDA decreased by 15% in the last fiscal year.

In the most recent fiscal year, Sight Sciences reported gross margin of 86%, EBITDA margin of (34%), and net margin of (50%).

See estimated margins and future growth rates for Sight Sciences

Sight Sciences Margins

Last FY202420252026202720282029
Gross Margin86%85%86%85%
EBITDA Margin(34%)(57%)(42%)(26%)
EBIT Margin(48%)(63%)(48%)(47%)
Net Margin(50%)(64%)(50%)(45%)
FCF Margin(39%)(28%)(39%)-

Sight Sciences Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth11%(1%)(3%)11%
Gross Profit Growth10%(1%)(2%)10%
EBITDA Growth(15%)(7%)(29%)(32%)
EBIT Growth9%(12%)(27%)9%
Net Profit Growth1%(7%)(25%)1%
FCF Growth-(53%)32%-

Data powered by FactSet, Inc. and Morningstar, Inc.

Sight Sciences Operational KPIs

Sight Sciences' revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.5M for the same period.

Sight Sciences' Rule of 40 is (15%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Sight Sciences' Rule of X is 2% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Sight Sciences
LTMLast FY202320242025202620272028
Rule of 40(19%)(15%)---
Bessemer Rule of X(2%)2%---
Revenue per Employee-$0.4M---
Opex per Employee-$0.5M---
R&D Expenses to Revenue17%19%22%23%19%
Opex to Revenue-134%156%149%134%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Sight Sciences Competitors

Sight Sciences competitors include Affluent Medical, Profound Medical, Orchestra BioMed, Stratec, Dong-A ST, Treace Medical Concepts, Median Technologies, Onward Medical, Carvolix and Eurobio Scientific.

Most Sight Sciences public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Affluent Medical-372.7x-(11.9x)
Profound Medical12.1x9.6x(5.3x)(5.8x)
Orchestra BioMed4.6x7.9x(3.0x)(2.2x)
Stratec1.3x1.2x9.1x8.7x
Dong-A ST0.8x0.8x11.0x10.4x
Treace Medical Concepts1.2x1.2x(62.9x)(53.1x)
Median Technologies9.3x8.8x(13.7x)(13.8x)
Onward Medical26.3x15.7x(3.6x)(2.8x)

This data is available for Pro users. Sign up to see all Sight Sciences competitors and their valuation data.

Start Free Trial

Sight Sciences VC Funding History

Before going public, Sight Sciences raised $108M in total equity funding, across 6 rounds.


Sight Sciences Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Dec-20Undisclosed stage-$23M-Sight Sciences, Inc. is a commercial-stage ophthalmic medical device company developing products for glaucoma and dry eye diseases. The company offers devices like the TearCare System for meibomian gland dysfunction-related dry eye, with noted precautions and potential adverse events such as eyelid irritation or thermal injury. In a Series B financing round announced around 2020, the company closed $7 million led by Hicks Equity Partners, with participation from all Series A investors including Scientific Health Development, Allegro Investment Fund, and others; the round was oversubscribed. Later funding included $56M of growth capital in September to advance standalone MIGS and procedure-based dry eye markets, and a $30M Series E in 2020.
Mar-20Series ED1 Capital Partners$30M-Sight Sciences, Inc. is a Menlo Park, California-based growth-stage medical device company focused on glaucoma and dry eye disease, the two fastest-growing segments in ophthalmology and optometry. Its key products include OMNI for minimally invasive glaucoma surgery (MIGS) and TearCare for procedure-based dry eye therapy. On March 18, 2020, the company closed an over $30 million Series E Preferred Stock financing round led by D1 Capital Partners, with proceeds allocated to clinical and operational development and commercial expansion of OMNI and TearCare. D1 Capital Partners, founded in 2018 by Daniel Sundheim with $10 billion under management at the time, invests across sectors including healthcare. James Rogers, an analyst at D1, highlighted the unmatched safety, efficacy, and versatility of OMNI and the early commercialization success of TearCare. Company executives, including CEO Paul Badawi and CFO Jesse Selnick, emphasized the investment's validation of progress and alignment for long-term growth amid large addressable markets: 80 million people globally affected by glaucoma and 350 million by dry eye disease. Later developments included a Series F financing in December 2020 led by D1 and Janus Henderson Investors, with a refinanced credit facility from MidCap Financial, to further clinical and commercial efforts. The company estimated U.S. market opportunities at $6 billion for glaucoma (OMNI) and $10 billion for dry eye.
Sep-19Series DKCK; MidCap Financial$31M-Sight Sciences, a Menlo Park-based medical device company, develops technologies for glaucoma and dry eye treatment, including the OMNI Surgical System for minimally invasive glaucoma surgery (MIGS) and the TearCare System for evaporative dry eye. In September 2019, the company closed $31 million in Series D preferred stock financing led by KCK Group, with participation from MidCap Financial, which had provided a $25 million debt facility earlier in 2019, for total proceeds of $56 million. The funds supported U.S. growth of OMNI and TearCare, international expansion, clinical trials, and new product development. KCK Managing Director Valeska Schroeder highlighted OMNI's innovation in targeting outflow resistance for standalone MIGS and TearCare's potential in dry eye, joining the board post-investment. Company executives, including CFO Jesse Selnick and CCO Shawn O'Neil, emphasized KCK's medtech expertise and market traction in MIGS and procedure-based dry eye.
Oct-17Series CAllegro Investment Fund$10M-Sight Sciences raised $10 million in a Series C funding round led by Allegro Investment Fund in October 2017. The round was oversubscribed with full participation from existing Series A and Series B investors. The Menlo Park, California-based company is a venture-backed, commercial-stage ophthalmic medical device company developing technologies for glaucoma and dry eye treatment, including surgical devices TRAB 360 and VISCO 360, and a heat therapy treatment called TearCare. The capital was allocated to accelerate commercialization and further development of its dry eye and surgical device offerings. The company also strengthened its leadership team during this period by recruiting a seasoned ophthalmic industry executive from Alcon to lead sales and commercial scale-up efforts.
Mar-16Series BHicks Equity Partners$7M-Sight Sciences, Inc. is a commercial-stage ophthalmic medical device company. In March 2016, it closed a $7 million Series B financing round led by Hicks Equity Partners, with participation from all Series A investors including Scientific Health Development, Allegro Investment Fund, and other institutional and angel investors. The round was oversubscribed.
Oct-15Series AAllegro Investment Fund; Scientific Health Development Partners$7M-Sight Sciences is a medical device company developing treatments for ophthalmic conditions including glaucoma and dry eye. Scientific Health Development Partners led the $7 million Series B financing round on approximately October 30, 2015, with participation from Allegro Investment Fund and all prior Series A investors. The company later progressed through additional financings, including a Preferred B round in June 2021 with a post-money valuation of $65,862,230, and a Preferred C3 round referenced in 2020. Sight Sciences went public via IPO in July 2021 and distributed shares to limited partners in March 2022.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Sight Sciences

When was Sight Sciences founded?Sight Sciences was founded in 2010.
Where is Sight Sciences headquartered?Sight Sciences is headquartered in United States.
How many employees does Sight Sciences have?As of today, Sight Sciences has over 216 employees.
Who is the CEO of Sight Sciences?Sight Sciences' CEO is Paul Badawi.
Is Sight Sciences publicly listed?Yes, Sight Sciences is a public company listed on Nasdaq.
What is the stock symbol of Sight Sciences?Sight Sciences trades under SGHT ticker.
When did Sight Sciences go public?Sight Sciences went public in 2021.
Who are competitors of Sight Sciences?Sight Sciences main competitors include Affluent Medical, Profound Medical, Orchestra BioMed, Stratec, Dong-A ST, Treace Medical Concepts, Median Technologies, Onward Medical, Carvolix, Eurobio Scientific.
What is the current market cap of Sight Sciences?Sight Sciences' current market cap is $236M.
What is the current revenue of Sight Sciences?Sight Sciences' last 12 months revenue is $81M.
What is the current revenue growth of Sight Sciences?Sight Sciences revenue growth (NTM/LTM) is 11%.
What is the current EV/Revenue multiple of Sight Sciences?Current revenue multiple of Sight Sciences is 2.4x.
Is Sight Sciences profitable?No, Sight Sciences is not profitable.
What is the current EBITDA of Sight Sciences?Sight Sciences has negative EBITDA and is not profitable.
What is Sight Sciences' EBITDA margin?Sight Sciences' last 12 months EBITDA margin is (30%).
What is the current EV/EBITDA multiple of Sight Sciences?Current EBITDA multiple of Sight Sciences is (7.8x).
How many companies Sight Sciences has acquired to date?Sight Sciences hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Sight Sciences has invested to date?Sight Sciences hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Sight Sciences

Lists including Sight Sciences

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial